Drug Development Pipeline
Restore CFTR Protein
SION-638 is a corrector, a type of CFTR modulator designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. Once it reaches the cell surface, CFTR protein forms a channel to allow chloride and sodium (salt) to move in and out of the cell.
A Phase 1 study to test the safety and tolerability of SION-638 in healthy volunteers is currently underway. Future studies are planned to evaluate SION-638 in people with CF who have the F508del CFTR mutation.
This program is sponsored by Sionna Therapeutics and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More